Status:
COMPLETED
A Pilot Study to Determine the Bioavailability of Oral Beta-Aminoisobutyric Acid (BAIBA) Ingestion
Lead Sponsor:
Lindenwood University
Collaborating Sponsors:
NNB Nutrition
Conditions:
Absorption; Chemicals
Eligibility:
All Genders
18-50 years
Phase:
NA
Brief Summary
Think of this section as your research "elevator pitch." Please briefly describe the question(s) or issues you are addressing with your research (limited to 100 words). You will be able to provide inf...
Detailed Description
Once determined eligible and provided consent, participants will be assigned in a randomized, double-blind, placebo-controlled, crossover fashion. Eligible study participants will complete one of five...
Eligibility Criteria
Inclusion
- All participants will be between the ages of 18-50 years
- All participants will be required to abstain from taking any amino acid (i.e., BCAAs, creatine, - beta-alanine, carnitine, etc.) for 14 days prior to beginning this study and for the entire duration -of the study
- Body mass index between 18.5 - 29.9 kg/m2
- Report accumulating at least 30 minutes of physical activity three days per week
- All participants will be determined to be healthy through completion of a detailed health history questionnaires
Exclusion
- Are less than 18 or greater than 50 years of age. Participants younger than 18 are excluded due to necessity of parental consent. Participants greater than 50 years old are excluded due to the anticipated age-related changes that occur in digestive function, medication use, and other - associated confounding comorbidities.
- Have a body mass index \< 18.5 and \> 29.9 kg/m2. Any participant with a BMI \> 29.9 kg/m2 must have a body fat percentage below 30% to be eligible.
- No individuals with a BMI above 32.0 kg/m2 will be eligible, irrespective of their body composition.
- Have a fasting capillary glucose (-30 minutes) level \> 110 mg/dL on two separate occasions.
- Currently smoke or have quit smoking within the past six months
- Are currently following a ketogenic diet or a very low-carbohydrate diet for the past 30 days.
- Any individual who is currently being treated for or diagnosed with a cardiac, respiratory, circulatory, musculoskeletal, metabolic, obesity, immune, autoimmune, psychiatric, hematological, neurological or endocrinological disorder or disease will be excluded.
- Report accumulating less than 30 minutes of physical activity per day for at least three days per week.
- Do not or are not willing to abstain from alcohol, nicotine and caffeine for 12 hours prior to each visit will be excluded
- Do not or are not willing to abstain from exercise for 24 hours prior to each visit will be excluded.
Key Trial Info
Start Date :
November 20 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2022
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT05328271
Start Date
November 20 2020
End Date
February 1 2022
Last Update
April 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lindenwood University
Saint Charles, Missouri, United States, 63301